Single answer
Is Abivax SA (ABVX) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $2.31 or 130.60%
(In 23 weeks 10 hours 27 minutes and 35 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Abivax SA is $135.38, which is $0.525 (0.39%) above the current price today's price.
Low target: $74.00 | High target: $176.00
Company snapshot
A quick overview of the business and its public profile.
ABIVAX Societe Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases infectious diseases and cancer in France Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohns Disease as well as for COVID19 Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV It also develops ABX 196 an immune enhancer candidate that is in Phase 12 clinical trials for the treatment of hepatocellular cancer In addition the company engages in the research programs for the treatment of Dengue fever influenza and respiratory syncytial virus ABIVAX Societe Anonyme has license contracts with the French National Centre for Scientific Research the University of Montpellier and the Institut Curie The company was incorporated in 2013 and is headquartered in Paris France
Website: https://www.abivax.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.71. Cash flow to debt ratio: -1.60. Net profit margin: -2,075.06%. Inflation risk score: high (1.00/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Abivax SA is $130.8M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Abivax SA 10 years ago, but if you had invested on 2023-10-19 when the price was $0.0000, you would have made a profit of $138.34 per share or 1,383,399,900.00%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.